Federal research funding now blocked from foreign collaboration—with broad waiver loopholes
S. 4525 — Securing Innovation and Research from Adversaries Act · Filed by Jim Banks (R-IN) · Introduced May 14, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill prohibits federal research funding from being used to collaborate with entities on U.S. government restricted lists (including Chinese military companies, sanctioned entities, and others designated for national security reasons). Federal agencies can grant case-by-case waivers if collaboration is necessary for national security or critical scientific purposes, and must report waivers to Congress within 30 days.
Why we flagged it
The bill's core function is to restrict federal research funding from flowing to collaboration with foreign entities on government restricted lists, with national security as the stated rationale. It is a security-focused research governance measure, not a substantive research policy or appropriation.
What the text implies
- Waiver authority is broad and discretionary (agency heads decide case-by-case), creating potential for inconsistent enforcement across agencies and possible political influence on which collaborations are permitted.
- The definition of 'research collaboration' is expansive (including data sharing, co-authorship, personnel exchanges, and 'any other arrangement' determined by agency heads), meaning compliance burden may extend beyond direct joint projects to routine academic communication.
The full analysis lists 5 implications of this text.
Who stands to gain
U.S. defense contractors and national security-focused research firms; Domestic semiconductor and biotechnology companies (protected from foreign competition in federally; Compliance and legal services firms (audit, monitoring, waiver documentation)